Stocktoria
REGENXBIO Inc. RGNX
REGENXBIO Inc. (RGNX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $170.4M at a -113.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.36 |
| Retained earnings / assets | -2.486 |
| EBIT / assets | -0.356 |
| Equity / liabilities | 0.293 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | 3/9 | -7.82 | — | +104.5% |
| ADAPY | Adaptimmune Therapeutics PLC | 3/9 | -13.03 | — | +195.3% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
FAQ
Is RGNX financially healthy?
REGENXBIO Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RGNX pay a dividend?
No, REGENXBIO Inc. does not currently pay a dividend.
How profitable is RGNX?
In FY2025, REGENXBIO Inc. had a net margin of -113.8% and a return on equity of -188.7%.
What is the analyst price target for RGNX?
The average Wall-Street price target for REGENXBIO Inc. is $24.36, about 123.3% above the recent price, from 11 analysts (consensus: buy).
Is RGNX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on REGENXBIO Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.